OPTN - Earnings announcements

YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the cancellation of its earnings conference call for the quarter and full year ended December 31, 2024 that had originally been scheduled for March 20, 2025 at 8:00 a.m. Eastern Time. The call is being cancelled due to the announcement earlier today that Optinose has entered into a definitive agreement to be acquired by Paratek Pharmaceuticals, subject to shareholder and other customary closing conditions. The Company now expects to report results for the three- and twelve-month periods ended D

YARDLEY, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the fourth quarter and full year of 2024 and corporate updates, before market open, on Thursday, March 20, 2025. Company to Host Conference CallMembers of the Company's leadership team will host a conference call to discuss financial results and corporate updates. The call is scheduled to start at 8:00 a.m. Eastern Time on Thursday, March 20, 2025. Participants may access the conference call live via webcast by visiting the Investors section of Opti

Company reports Q3 2024 XHANCE net revenue of $20.4 million, an increase of 3% compared to Q3 2023 Company reports positive inflection in new prescriptions of XHANCE starting in September Company decreases full year 2024 XHANCE net revenue guidance to be between $75.0 to $79.0 million and increases expected average net revenue per prescription guidance to be approximately $270 Company decreases full year 2024 operating expenses guidance to be between $90.0 to $93.0 million Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and

YARDLEY, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the third quarter 2024 and corporate updates, before market open, on Tuesday, November 12, 2024. Company to Host Conference CallMembers of the Company's leadership team will host a conference call to discuss financial results and corporate updates. The call is scheduled to start at 8:00 a.m. Eastern Time on Tuesday, November 12, 2024. Participants may access the conference call live via webcast by visiting the Investors section of Optinose's website

YARDLEY, Pa., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the second quarter 2024 and corporate updates, before market open, on Thursday, August 8, 2024. Company to Host Conference CallMembers of the Company's leadership team will host a conference call to discuss financial results and corporate updates. The call is scheduled to start at 8:00 a.m. Eastern Time on Thursday, August 8, 2024. Participants may access the conference call live via webcast by visiting the Investors section of Optinose's website at

YARDLEY, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the first quarter 2024 and corporate updates, before market open, on Tuesday, May 14, 2024. Company to Host Conference CallMembers of the Company's leadership team will host a conference call to discuss financial results and corporate updates. The call is scheduled to start at 10:00 a.m. Eastern Time on Tuesday, May 14, 2024. Participants may access the conference call live via webcast by visiting the Investors section of Optinose's website at http://

YARDLEY, Pa., April 25, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced corporate updates detailing its commercial plans and expectations for XHANCE® (fluticasone propionate) following the recent FDA approval of a new indication for the treatment of chronic rhinosinusitis without nasal polyps in patients 18 year of age and older. The Company will host an investor call at 10:00 a.m. Eastern Time today to discuss its commercial strategy and financial outlook. In addition, the Company announced preliminary XHANCE net product revenue of $14.9 million for the three mon

PDUFA target action date is March 16, 2024, for the Company's sNDA. If approved, the Company is prepared for launch of XHANCE for treatment of patients diagnosed with chronic sinusitis Physicians diagnose chronic sinusitis 10 times more frequently than XHANCE's current nasal polyps indication and there is no FDA-approved medication for these patients Company reports fourth quarter and full year 2023 XHANCE net revenue of $19.9 million and $71.0 million Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and aller

YARDLEY, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the fourth quarter 2023 and corporate updates, before market open on Thursday, March 7, 2024. Company to Host Conference CallMembers of the Company's leadership team will host a conference call to discuss financial results and corporate updates. The call is scheduled to start at 8:00 a.m. Eastern Time on Thursday, March 7, 2024. Participants may access the conference call live via webcast by visiting the Investors section of Optinose's website at htt

Company reports third quarter 2023 XHANCE net revenue of $19.8 million and increases full year 2023 XHANCE net revenue guidance Strong improvement in operating efficiency as SG&A and R&D expenses decreased by $32M or 33% year-to-date PDUFA goal date for XHANCE Chronic Rhinosinusitis sNDA is December 16, 2023 Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) --  Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended September 30, 2023, and provided operational updates. "We are excited as we

YARDLEY, Pa., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the third quarter 2023 and corporate updates, before market open on Thursday, November 9, 2023. Company to Host Conference CallMembers of the Company's leadership team will host a conference call to discuss financial results and corporate updates. The call is scheduled to start at 8:00 a.m. Eastern Time on Thursday, November 9, 2023. Participants may access the conference call live via webcast by visiting the Investors section of Optinose's website a

Company reports second quarter 2023 XHANCE net revenue of $19.5 million and increases full year 2023 XHANCE net revenue guidance Strong improvement in operating efficiency in the first half of 2023 as SG&A and R&D expenses decreased by $22M or 33% compared to first half 2022 Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended June 30, 2023, and provided operational updates. "We are pleased with the progress we made in the second quart

Second Quarter 2023 Conference Call and Webcast to be held August 10, 2023 at 8:00 a.m. Eastern Time Company plans to update full year 2023 XHANCE net revenue guidance on August 10 YARDLEY, Pa., July 27, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced preliminary XHANCE® (fluticasone propionate) net product revenue of $19.5 million for the three months ended June 30, 2023. "Our preliminary second quarter net product revenue of $19.5 million contributes to a first half 2023 performance that exceeded our initial expectations," stated CEO Ram

Strong progress towards strategic objectives including acceptance of sNDA for review and prioritization of potential launch of XHANCE as first drug approved to treat chronic rhinosinusitis Company reports first quarter 2023 XHANCE net revenue of $11.8 million Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., May 11, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended March 31, 2023, and provided operational updates. "We are pleased with the progress we made in the first quarter of 2023 towards

YARDLEY, Pa., May 01, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the first quarter 2023 and corporate updates, before market open on Thursday, May 11, 2023. Company to Host Conference CallMembers of the Company's leadership team will host a conference call to discuss financial results and corporate updates. The call is scheduled to start at 8:00 a.m. Eastern Time on Thursday, May 11, 2023. Participants may access the conference call live via webcast by visiting the Investors section of Optinose's website at http://

Company reports fourth quarter and full year 2022 XHANCE net revenue of $20.9 million and $76.3 million Company submitted sNDA for XHANCE label expansion in February 2023 Physicians diagnose chronic sinusitis 10 times more frequently than XHANCE's current nasal polyps indication and there is no FDA-approved medication for these patients Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter and year ended Decemb

Company plans to submit an sNDA for XHANCE as a treatment for chronic sinusitis in early 2023 Physicians Diagnose Chronic Sinusitis 10 Times More Frequently Than XHANCE's Current Nasal Polyps Indication and there is no FDA-Approved Medication for these Patients Company reports third quarter 2022 XHANCE net revenue of $20.1 million Company expects full year 2022 XHANCE net revenue to be between $74 to $78 million Company expects full year 2022 operating expenses to be between $127 to $131 million; full year 2023 operating expenses expected to decrease materially Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Opti

YARDLEY, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the third quarter 2022 and corporate updates, before market open on Thursday, November 10, 2022. Company to Host Conference CallMembers of the Company's leadership team will host a conference call to discuss financial results and corporate updates. The call is scheduled to start at 8:00 a.m. Eastern Time on Thursday, November 10, 2022. Participants may access the conference call live via webcast by visiting the Investors section of Optinose's website

Company reports second quarter XHANCE net revenue of $20.6 million increased 12% compared to second quarter 2021 Company plans to submit an sNDA for XHANCE as a treatment for chronic sinusitis by the end of 2022 Company expects full year 2022 XHANCE net revenue to be between $85 to $92 million Company expects full year 2022 and operating expenses to be between $129 to $134 million Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the qu

YARDLEY, Pa., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the second quarter 2022 and corporate updates, before market open on Thursday, August 11, 2022. Company to Host Conference CallMembers of the Company's leadership team will host a conference call to discuss financial results and corporate updates. The call is scheduled to start at 8:00 a.m. Eastern Time on Thursday, August 11, 2022. Participants may access the conference call live via webcast by visiting the Investors section of Optinose's website at

First Ever Phase 3 Program to Show Improvement in Both Symptoms and Inflammation Inside the Sinuses with a Nasal Therapy for Chronic Sinusitis Patients Physicians Diagnose Chronic Sinusitis 10 Times More Frequently Than XHANCE's Current Nasal Polyps Indication and there is no FDA-Approved Medication for these Patients Conference call and webcast to be held today at 8:30 a.m. Eastern Time YARDLEY, Pa., June 13, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the statistically significant benefits of XHANCE in the ReOpen2 trial for both the symptoms co-primary endpo

Company reports first quarter XHANCE net revenue of $14.8 million increased 35% compared to first quarter 2021 Company expects top-line results from the second of two clinical trials evaluating XHANCE as a potential treatment for Chronic Sinusitis in June 2022 Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., May 12, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended March 31, 2022, and provided operational updates. "XHANCE net revenue increased 35% in the first quarter of 2022 compared to fi

Conference Call and Webcast to be held May 12, 2022, at 8:00 a.m. Eastern Time YARDLEY, Pa., May 05, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the first quarter 2022 and corporate updates, before market open on Thursday, May 12, 2022. Company to Host Conference CallMembers of the Company's leadership team will host a conference call to discuss financial results and corporate updates. The call is scheduled to start at 8:00 a.m. Eastern Time on Thursday, May 12, 2022. To participate on the conference call, please d

XHANCE met both co-primary endpoints in the ReOpen1 trial, demonstrating statistically significant benefits on symptoms and CT scans in patients with chronic sinusitis There are no FDA-approved drug treatments for the 30 million adults in the U.S. with chronic sinusitis Conference call and webcast to be held today at 4:15 p.m. Eastern Time YARDLEY, Pa., March 07, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the ReOpen1 clinical trial met both of its co-primary endpoints. A statistically significant improvement was demonstrated in patients with chronic sinu

Conference Call and Webcast to be held March 8, 2021 at 8:00 a.m. Eastern Time Company to Present at the Cowen 42nd Annual Health Care Conference on March 9, 2022 YARDLEY, Pa., March 04, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the fourth quarter 2021 and corporate updates, before market open on Tuesday, March 8, 2022. Company to Host Conference CallMembers of the Company's leadership team will host a conference call to discuss financial results and corporate updates. The call is scheduled to start

Third quarter 2021 XHANCE net revenue of $22 million increased 41% compared to third quarter 2020 Third quarter 2021 XHANCE prescriptions increased 25% from third quarter 2020 Conference call and webcast to be held tomorrow at 8:30 a.m. Eastern Time YARDLEY, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended September 30, 2021, and provided operational updates. "We continued to make progress during third quarter 2021 towards our objectives of growing XHANCE and successfully completing our chronic sinusitis progra

Conference Call and Webcast to be held November 16, 2021 at 8:30 a.m. Eastern Time YARDLEY, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the third quarter 2021 and corporate updates, after market close on Monday, November 15, 2021 and host a conference call and webcast before market open on Tuesday, November 16, 2021. Company to Host Conference CallMembers of the Company's leadership team will host a conference call to discuss financial results and corporate updates. The call is scheduled to start at 8:

Second quarter 2021 XHANCE net revenue of $18.4 million increased 79% compared to second quarter 2020 Second quarter 2021 XHANCE prescriptions increased 33% from second quarter 2020 Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended June 30, 2021, and provided operational updates. "We are pleased with the progress we made in second quarter 2021 towards our objectives of growing XHANCE and successfully completing our chronic sinusitis

Preliminary XHANCE Net Revenue Growth of 79% Compared to Second Quarter 2020 Company reiterates XHANCE Net Revenue guidance for the Full Year of 2021 to be at least $80 million Conference Call and Webcast to be held August 11, 2021 at 8:00 a.m. Eastern Time YARDLEY, Pa., July 28, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced preliminary XHANCE® (fluticasone propionate) net product revenue of $18.4 million for the three months ended June 30, 2021. This represents a 79% increase compared to the three months ended June 30, 2020, and a 67% increase compared to the